Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases
- Conditions
- Interventions
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2015-02-03
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 10
- Registration Number
- NCT01417403
- Locations
- 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2013-02-26
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT01396200
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Preventive Approach to Congenital Heart Block With Hydroxychloroquine
- Conditions
- Interventions
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 74
- Registration Number
- NCT01379573
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
- First Posted Date
- 2011-03-31
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 32
- Registration Number
- NCT01326533
- Locations
- 🇺🇸
University of Pittsburgh, Montefiore Hospital, Pittsburgh, Pennsylvania, United States
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01273805
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 143
- Registration Number
- NCT01266057
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 12
- Registration Number
- NCT01232660
- Locations
- 🇬🇧
St Stephen's Centre, London, United Kingdom
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
- Conditions
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Lynn McMahon
- Target Recruit Count
- 66
- Registration Number
- NCT01227135
- Locations
- 🇬🇧
Gartnavel General Hospital, Glasgow, Scotland, United Kingdom
🇬🇧Imperial College London, London, England, United Kingdom
🇬🇧Royal Liverpool University Hospital, Liverpool, England, United Kingdom
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
- Conditions
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT01206530
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Pharmacological Treatment In Osteoarthritis
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Maasstad Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01148043
- Locations
- 🇳🇱
Sint Franciscus Gasthuis, Rotterdam, Netherlands
🇳🇱Vlietland Hospital, Schiedam, Netherlands
🇳🇱ZorgSaam Zeeuws-Vlaanderen, Terneuzen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.